Compare UEIC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | XLO |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 56.9M |
| IPO Year | 1995 | 2021 |
| Metric | UEIC | XLO |
|---|---|---|
| Price | $5.17 | $9.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 60.1K | 9.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $368,288,000.00 | $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.69 | $0.46 |
| 52 Week High | $5.99 | $9.90 |
| Indicator | UEIC | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 48.64 |
| Support Level | $4.12 | $8.63 |
| Resistance Level | $5.67 | $9.15 |
| Average True Range (ATR) | 0.24 | 0.24 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 50.91 | 21.83 |
Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.